What Do COVID-19 Vaccines Tell Us About Nucleic Acid Delivery In Vivo?
The utilization of the m RNA-based Pfizer-BioNTech and Moderna coronavirus disease 2019 (COVID-19) vaccines represents the culmination of many years of nonviral nucleic acid delivery, but more importantly, they signify a massive clinical scientific success . Scientists working in the area of nucleic...
Gespeichert in:
| Veröffentlicht in: | Nucleic acid therapeutics 2021-10, Vol.31 (5), p.321-323 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 323 |
|---|---|
| container_issue | 5 |
| container_start_page | 321 |
| container_title | Nucleic acid therapeutics |
| container_volume | 31 |
| creator | Hadjiargyrou, Michael |
| description | The utilization of the
m
RNA-based Pfizer-BioNTech and Moderna coronavirus disease 2019 (COVID-19) vaccines represents the culmination of many years of nonviral nucleic acid delivery, but more importantly, they signify a massive clinical
scientific success
. Scientists working in the area of nucleic acid delivery using lipid nanoparticles will undoubtedly be energized by the success of these vaccines and begin to collect much needed data in the realm of nonviral-based RNA
and DNA
delivery, specifically, the use of lipid nanoparticles, the immune response, safety, and efficacy. It is easily conceivable that in the future we can utilize these data to
help
streamline our approach for the delivery of
DNA
for gene therapy and
regulatory RNAs for
therapeutic and regenerative medicine (ie, wound repair) applications
. |
| doi_str_mv | 10.1089/nat.2021.0013 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8591056</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2581775534</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-138e5e1fe956a383a222439ef890b2e4721d7fa2be324191d79b8ee2aaa48d8b3</originalsourceid><addsrcrecordid>eNqFkUtrGzEURkVpaILrZbdF0E034-gx8kibBmPXjSHEm8RdCo18p1YYS4k0Y_C_j4xd02RTbfQ6fNyPg9AXSkaUSHXtTTdihNERIZR_QFeMClVwXoqP5zOvLtEwpSeSlyCklOITuuRcjYnk6grNf29Mh2cBT5erxaygCq-Mtc5Dwg_Qtvgx4Ukd-g7f97YFZ_HEujWeQet2EPd44fHK7cLNZ3TRmDbB8LQP0OP858P0trhb_lpMJ3eFLanoCsolCKANKDE2XHLDGCu5gkYqUjMoK0bXVWNYDZyVVOWLqiUAM8aUci1rPkA_jrnPfb2FtQXfRdPq5-i2Ju51ME6__fFuo_-EnZZCUSLGOeD7KSCGlx5Sp7cu2dzUeAh90kzkgYQiUmT02zv0KfTR53qZkrSqhOBlpoojZWNIKUJzHoYSfZCksyR9kKQPkjL_9d8GZ_qvkgzwI3B4Nt63DmqI3X9iXwEsE5tE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2581775534</pqid></control><display><type>article</type><title>What Do COVID-19 Vaccines Tell Us About Nucleic Acid Delivery In Vivo?</title><source>Alma/SFX Local Collection</source><creator>Hadjiargyrou, Michael</creator><creatorcontrib>Hadjiargyrou, Michael</creatorcontrib><description>The utilization of the
m
RNA-based Pfizer-BioNTech and Moderna coronavirus disease 2019 (COVID-19) vaccines represents the culmination of many years of nonviral nucleic acid delivery, but more importantly, they signify a massive clinical
scientific success
. Scientists working in the area of nucleic acid delivery using lipid nanoparticles will undoubtedly be energized by the success of these vaccines and begin to collect much needed data in the realm of nonviral-based RNA
and DNA
delivery, specifically, the use of lipid nanoparticles, the immune response, safety, and efficacy. It is easily conceivable that in the future we can utilize these data to
help
streamline our approach for the delivery of
DNA
for gene therapy and
regulatory RNAs for
therapeutic and regenerative medicine (ie, wound repair) applications
.</description><identifier>ISSN: 2159-3337</identifier><identifier>EISSN: 2159-3345</identifier><identifier>DOI: 10.1089/nat.2021.0013</identifier><identifier>PMID: 33960839</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc., publishers</publisher><subject>Coronaviruses ; COVID-19 ; COVID-19 vaccines ; Deoxyribonucleic acid ; DNA ; Gene therapy ; Immune response ; Issues in Development ; Lipids ; mRNA ; Nanoparticles ; Nucleic acids ; Regenerative medicine ; Vaccines ; Viral diseases ; Wound healing</subject><ispartof>Nucleic acid therapeutics, 2021-10, Vol.31 (5), p.321-323</ispartof><rights>2021, Mary Ann Liebert, Inc., publishers</rights><rights>Copyright Mary Ann Liebert, Inc. Oct 2021</rights><rights>Copyright 2021, Mary Ann Liebert, Inc., publishers 2021 Mary Ann Liebert, Inc., publishers</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c415t-138e5e1fe956a383a222439ef890b2e4721d7fa2be324191d79b8ee2aaa48d8b3</cites><orcidid>0000-0001-8927-2333</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33960839$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hadjiargyrou, Michael</creatorcontrib><title>What Do COVID-19 Vaccines Tell Us About Nucleic Acid Delivery In Vivo?</title><title>Nucleic acid therapeutics</title><addtitle>Nucleic Acid Ther</addtitle><description>The utilization of the
m
RNA-based Pfizer-BioNTech and Moderna coronavirus disease 2019 (COVID-19) vaccines represents the culmination of many years of nonviral nucleic acid delivery, but more importantly, they signify a massive clinical
scientific success
. Scientists working in the area of nucleic acid delivery using lipid nanoparticles will undoubtedly be energized by the success of these vaccines and begin to collect much needed data in the realm of nonviral-based RNA
and DNA
delivery, specifically, the use of lipid nanoparticles, the immune response, safety, and efficacy. It is easily conceivable that in the future we can utilize these data to
help
streamline our approach for the delivery of
DNA
for gene therapy and
regulatory RNAs for
therapeutic and regenerative medicine (ie, wound repair) applications
.</description><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 vaccines</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>Gene therapy</subject><subject>Immune response</subject><subject>Issues in Development</subject><subject>Lipids</subject><subject>mRNA</subject><subject>Nanoparticles</subject><subject>Nucleic acids</subject><subject>Regenerative medicine</subject><subject>Vaccines</subject><subject>Viral diseases</subject><subject>Wound healing</subject><issn>2159-3337</issn><issn>2159-3345</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqFkUtrGzEURkVpaILrZbdF0E034-gx8kibBmPXjSHEm8RdCo18p1YYS4k0Y_C_j4xd02RTbfQ6fNyPg9AXSkaUSHXtTTdihNERIZR_QFeMClVwXoqP5zOvLtEwpSeSlyCklOITuuRcjYnk6grNf29Mh2cBT5erxaygCq-Mtc5Dwg_Qtvgx4Ukd-g7f97YFZ_HEujWeQet2EPd44fHK7cLNZ3TRmDbB8LQP0OP858P0trhb_lpMJ3eFLanoCsolCKANKDE2XHLDGCu5gkYqUjMoK0bXVWNYDZyVVOWLqiUAM8aUci1rPkA_jrnPfb2FtQXfRdPq5-i2Ju51ME6__fFuo_-EnZZCUSLGOeD7KSCGlx5Sp7cu2dzUeAh90kzkgYQiUmT02zv0KfTR53qZkrSqhOBlpoojZWNIKUJzHoYSfZCksyR9kKQPkjL_9d8GZ_qvkgzwI3B4Nt63DmqI3X9iXwEsE5tE</recordid><startdate>20211001</startdate><enddate>20211001</enddate><creator>Hadjiargyrou, Michael</creator><general>Mary Ann Liebert, Inc., publishers</general><general>Mary Ann Liebert, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8927-2333</orcidid></search><sort><creationdate>20211001</creationdate><title>What Do COVID-19 Vaccines Tell Us About Nucleic Acid Delivery In Vivo?</title><author>Hadjiargyrou, Michael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-138e5e1fe956a383a222439ef890b2e4721d7fa2be324191d79b8ee2aaa48d8b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 vaccines</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>Gene therapy</topic><topic>Immune response</topic><topic>Issues in Development</topic><topic>Lipids</topic><topic>mRNA</topic><topic>Nanoparticles</topic><topic>Nucleic acids</topic><topic>Regenerative medicine</topic><topic>Vaccines</topic><topic>Viral diseases</topic><topic>Wound healing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hadjiargyrou, Michael</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Nucleic acid therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hadjiargyrou, Michael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>What Do COVID-19 Vaccines Tell Us About Nucleic Acid Delivery In Vivo?</atitle><jtitle>Nucleic acid therapeutics</jtitle><addtitle>Nucleic Acid Ther</addtitle><date>2021-10-01</date><risdate>2021</risdate><volume>31</volume><issue>5</issue><spage>321</spage><epage>323</epage><pages>321-323</pages><issn>2159-3337</issn><eissn>2159-3345</eissn><abstract>The utilization of the
m
RNA-based Pfizer-BioNTech and Moderna coronavirus disease 2019 (COVID-19) vaccines represents the culmination of many years of nonviral nucleic acid delivery, but more importantly, they signify a massive clinical
scientific success
. Scientists working in the area of nucleic acid delivery using lipid nanoparticles will undoubtedly be energized by the success of these vaccines and begin to collect much needed data in the realm of nonviral-based RNA
and DNA
delivery, specifically, the use of lipid nanoparticles, the immune response, safety, and efficacy. It is easily conceivable that in the future we can utilize these data to
help
streamline our approach for the delivery of
DNA
for gene therapy and
regulatory RNAs for
therapeutic and regenerative medicine (ie, wound repair) applications
.</abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc., publishers</pub><pmid>33960839</pmid><doi>10.1089/nat.2021.0013</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0001-8927-2333</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2159-3337 |
| ispartof | Nucleic acid therapeutics, 2021-10, Vol.31 (5), p.321-323 |
| issn | 2159-3337 2159-3345 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8591056 |
| source | Alma/SFX Local Collection |
| subjects | Coronaviruses COVID-19 COVID-19 vaccines Deoxyribonucleic acid DNA Gene therapy Immune response Issues in Development Lipids mRNA Nanoparticles Nucleic acids Regenerative medicine Vaccines Viral diseases Wound healing |
| title | What Do COVID-19 Vaccines Tell Us About Nucleic Acid Delivery In Vivo? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T15%3A52%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=What%20Do%20COVID-19%20Vaccines%20Tell%20Us%20About%20Nucleic%20Acid%20Delivery%20In%20Vivo?&rft.jtitle=Nucleic%20acid%20therapeutics&rft.au=Hadjiargyrou,%20Michael&rft.date=2021-10-01&rft.volume=31&rft.issue=5&rft.spage=321&rft.epage=323&rft.pages=321-323&rft.issn=2159-3337&rft.eissn=2159-3345&rft_id=info:doi/10.1089/nat.2021.0013&rft_dat=%3Cproquest_pubme%3E2581775534%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2581775534&rft_id=info:pmid/33960839&rfr_iscdi=true |